The Natural History and Treatment of Acute Hepatitis C Virus (HCV) in HIV-positive Individuals

PRospective OBservational Evaluation of the Natural History and Treatment of Acute HCV in HIV-positive Individuals: The PROBE-C Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01289652

Acronym

PROBE-C

Enrollment

600

Registered

2011-02-04

Start date

2011-05-31

Completion date

2017-04-30

Last updated

2014-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Hepatitis C, HIV

Keywords

Acute hepatitis C (HCV), Human immunodeficiency virus (HIV)

Brief summary

The aim of the study is to investigate the epidemiology, natural history and treatment outcomes of acute hepatitis C (HCV) infection. Given the current pattern of case reporting, the cohort will be largely made up of human immunodeficiency virus (HIV)-positive patients, but HIV-negative patients with acute hepatitis C (AHC) will also be enrolled to enable comparisons to be made as appropriate and possible.

Detailed description

In a multi-center, prospective, open cohort study, patients with documented acute hepatitis C infection will be followed prospectively over an initial time-period of 3 years after diagnosis of acute hepatitis C infection to investigate: 1. epidemiology * to describe the characteristics of patients who have acquired acute HCV infection, including examination of regional differences in modes of transmission, behavioural factors, concomitant sexually transmitted diseases, clinical presentation and associated laboratory test results. * characterization of the HCV strains circulating within the community using phylogenetic analysis 2. natural history * determination of the rate of spontaneous viral clearance, and the clinical, immunological, host genetic and viral factors associated with viral clearance * progression of liver disease after acute hepatitis C; including the use of non-invasive liver fibrosis markers to estimate rates of liver fibrosis progression 3. treatment strategies * describe the outcome of different treatment strategies for acute HCV infection, although it is acknowledged that there will be no random allocation of treatment strategies. * investigate factors associated with treatment response including time to initiation of therapy, duration of therapy, the use of ribavirin and genetic factors.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Documented current or past acute hepatitis C infection with detectable HCV-RNA (PCR-assay) with an estimated duration of 52 weeks at diagnosis as defined below: * First HCV RNA positive AND * Prior negative anti-HCV antibody or HCV RNA test within 12 months OR * Rise of liver transaminases above 2.5 x upper limit of normal (ULN) within the past 12 months with prior normal transaminases during the year before AND * Exclusion of other causes of acute hepatitis

Exclusion criteria

* Acute liver disease other than hepatitis C * Inability to provide written informed consent * Younger than 18 years of age

Design outcomes

Primary

Measure	Time frame
SVR	3 years

Countries

Germany

Contacts

Primary ContactJuergen K Rockstroh, MD

juergen.rockstroh@ukb.uni-bonn.de

Backup ContactChristoph Boesecke, MD

christoph.boesecke@ukb.uni-bonn.de

Outcome results